Clinical Trials on Adult Solid Tumor

Total 20244 results

Jacobio Pharmaceuticals Co., Ltd.

Recruiting

A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors

Solid Tumors, Adult

United States
HighField Biopharmaceuticals Corporation

Recruiting

A Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors

Solid Tumors, Adult

China, United States
NEC OncoImmunity AS

Recruiting

NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors

Solid Tumors, Adult

Lithuania
Shanghai East Hospital
Nanjing Legend Biotech Co.

Terminated

A Clinical Study to Evaluate CAR-T Cell-based Medicinal Product in the Treatment of Advanced Solid Tumors

Solid Tumors, Adult

China
Wuxi People's Hospital

Recruiting

Clinical Study on the Treatment of Advanced Recurrent Tumors With Anticancer Mouse Characteristic Human Neutrophils

Advanced Cancer | Solid Tumor, Adult

China
University of Nebraska
National Cancer Institute (NCI)

Completed

Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Roswell Park Cancer Institute
TetraLogic Pharmaceuticals

Terminated

Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Nektar Therapeutics

Completed

A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors (NKTR-214)

Unspecified Adult Solid Tumor, Protocol Specific

United States
UMC Utrecht

Completed

A Study to Identify a Biomarker Predictive for Response on Everolimus in Solid Tumors (CPCT-03) (CPCT-03)

Unspecified Adult Solid Tumor, Protocol Specific

Netherlands
University of California, Davis
Bayer

Completed

Sorafenib in Treating Patients With Advanced Malignant Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
University of Southern California
National Cancer Institute (NCI); Jina Pharmaceuticals Inc.

Completed

Nanosomal Docetaxel Lipid Suspension in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
University of California, San Francisco
National Cancer Institute (NCI)

Completed

Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

PET and/or MRI Scans in Assessing Tumor Response in Patients Receiving Antiangiogenesis Therapy

Unspecified Adult Solid Tumor, Protocol Specific

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Interleukin-2 Plus Monoclonal Antibody Therapy in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Abramson Cancer Center of the University of Pennsylvania
National Cancer Institute (NCI)

Completed

Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Huang Lian (Chinese Herb) in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Genentech, Inc.
National Cancer Institute (NCI); Sidney Kimmel Comprehensive Cancer Center...

Completed

GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific
Southwest Oncology Group
National Cancer Institute (NCI)

Withdrawn

S0718 Pazopanib and Temsirolimus in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific
National Cancer Institute (NCI)

Completed

Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

SJG-136 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery

Unspecified Adult Solid Tumor, Protocol Specific

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Unknown

CP-609,754 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
University of Pittsburgh
National Cancer Institute (NCI)

Completed

Calcitriol Plus Paclitaxel in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Terminated

AFP464 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Institute of Cancer Research, United Kingdom
National Cancer Institute (NCI)

Unknown

17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (17-DMAG) in Treating Patients With Metastatic Solid Tumors or Tumors That Cannot Be Removed By Surgery

Unspecified Adult Solid Tumor, Protocol Specific

United Kingdom
National Cancer Institute (NCI)

Completed

UCN-01 and Carboplatin in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Ro 31-7453 in Treating Patients With Locally Advanced or Metastatic Solid Tumor

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Ro 31-7453 in Treating Patients With Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Cancer Research UK

Completed

Aurora B/C Kinase Inhibitor GSK1070916A in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United Kingdom
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Safingol and Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Dale Shepard, MD, PhD
National Cancer Institute (NCI)

Terminated

Hsp90 Inhibitor AUY922 in Treating Older Patients With Advanced Solid Malignancies

Unspecified Adult Solid Tumor, Protocol Specific

United States
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

SU5416, Irinotecan, and Cisplatin in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

GTI-2040 and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

KRN5500 in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
European Organisation for Research and Treatment...

Completed

Mistletoe Lectin in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy

Unspecified Adult Solid Tumor, Protocol Specific

Germany, France
European Organisation for Research and Treatment...

Suspended

BIBX 1382 in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

France, Netherlands, Norway, Belgium, Switzerland, Austria, United Kingdom, Germany, Denmark
European Organisation for Research and Treatment...

Withdrawn

CHS 828 in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

France, Norway, Switzerland, Netherlands, Belgium, Austria, United Kingdom, Denmark, Germany
European Organisation for Research and Treatment...

Completed

E7070 in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

France, Netherlands, Norway, Belgium, Switzerland, Austria, United Kingdom, Germany, Denmark
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
University of California, Davis
Bristol-Myers Squibb; National Cancer Institute (NCI); Genentech, Inc.

Terminated

Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors (UCDCC#207)

Unspecified Adult Solid Tumor, Protocol Specific

United States
The Cleveland Clinic
National Cancer Institute (NCI)

Completed

Lenalidomide, Docetaxel, and Carboplatin in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific
Proacta, Incorporated

Completed

PR104 and G-CSF in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States, New Zealand
Proacta, Incorporated

Completed

A Phase I Dose Escalation Trial of PR104 Given Weekly in Subjects With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

New Zealand
Hoag Memorial Hospital Presbyterian
Cancer Biotherapy Research Group

Completed

Tumor Cell Vaccine in Treating Patients With Advanced Cancer

Unspecified Adult Solid Tumor, Protocol Specific

United States
Roswell Park Cancer Institute

Completed

Irinotecan Followed by Fluorouracil in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States

Clinical Trials on Adult Solid Tumor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations